
# Central African Republic ALMA Quarterly Report Quarter Four, 2022




## **Scorecard for Accountability and Action**



Commodities Financed		
LLIN financing 2022 projection (% of need)		100
Public sector RDT financing 2022 projection (% of need)		100
Public sector ACT financing 2022 projection (% of need)		100
Policy		
Signed, ratified and deposited the AMA instrument at the AUC		
Malaria activities targeting refugees in Malaria Strategic Plan		
Malaria activities targeting IDPs in Malaria Strategic Plan		
Country Reporting Launch of Zero Malaria Starts with Me Campaign		
Resistance Monitoring, Implementation and Impact		
Drug Resistance Monitoring Conducted (2018-2020) and data reported to WHO		
Insecticide classes with mosquito resistance in representative sentinel sites confirmed since 2010		4
Insecticide resistance monitored since 2015 and data reported to WHO		
National Insecticide Resistance Monitoring and Management Plan		
RDTs in stock (>6 months stock)		
ACTs in stock (>6 months stock)		
LLIN/IRS campaign on track		
Operational LLIN/IRS coverage (% of at risk population)		100
On track to reduce case incidence by ≥40% by 2021 (vs 2015)		
On track to reduce case mortality by ≥40% by 2021 (vs 2015)		
Tracer Indicators for Maternal and Child Health, NTDs an	d C	ovid 19
Scale of Implementation of ICCM		
Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2021)	•	43
Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2021)		65
Vitamin A Coverage 2021 (2 doses)		
DPT3 coverage 2021 (vaccination among 0-11 month olds)		42
% Population Fully Vaccinated Against COVID-19		30

There is intense malaria transmission all year round in the Central African Republic and the entire population of the country is at high risk. The annual reported number of malaria cases in 2021 was 2,223,562 with 2,412 deaths.

## Key



## Central African Republic ALMA Quarterly Report, Quarter Four, 2022



### Malaria

#### **Global Fund Update**

The Global Fund has announced that Central African Republic will receive US\$140.2 million for HIV, tuberculosis, malaria, and health systems strengthening as the country allocation for 2024-2026. The Global Fund has determined the total allocation amount based on Central African Republic's disease burden and income level, as well as several other factors. The malaria component is also allocated a specific proportion of the total, according to a formula developed by the Global Fund that takes into account several factors, including disease burden and the importance of sustaining life-saving essential services. For Central African Republic this is calculated at US\$66.6 million. The allocations to the individual disease components are not fixed, and can be adjusted according to decisions made at country level. Central African Republic is urged to ensure that resources are allocated to malaria control from the overall Global Fund country allocation, as well as from domestic resources, to accelerate progress.

#### **Progress**

The country continues to work on strengthening and maintaining health services following the devastating impact of the COVID-19 pandemic. In this regard Central African Republic has procured sufficient LLINs to achieve universal operational coverage of the targeted at-risk population. Central African Republic has recently submitted insecticide resistance monitoring data to WHO and has carried out drug resistance testing since 2018 and has reported the results to WHO. The ACTs, RDTs and LLINs needed for 2022 are fully financed, and the country reports good stocks of ACTs and RDTs. The national strategic plan includes activities targeting IDPs.

#### **Impact**

The annual reported number of malaria cases in 2021 was 2,223,562 with 2,412 deaths.

#### **Key Challenges**

- Limited access to some at-risk populations is hampering coverage of malaria control interventions.
- Limited resources to further scale-up interventions.
- Sustaining the delivery of essential life-saving interventions during the COVID-19 pandemic including for Reproductive, Maternal, Newborn, Adolescent and Child health, malaria and Neglected Tropical Diseases.

**Previous Key Recommended Actions** 

Objective	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
Impact	Ensure that malaria services including case management and vector control are sustained and implemented whilst using COVID-19 sensitive guidelines during the pandemic	Q4 2022		The country continues the ITN distribution in Region 5 and is planning the distribution in regions 1, 2, 3 and 6. Diagnosis and treatment were implemented at health facility and community levels. Health facilities received stock of RDTs, ACTs, and ITNs for routine distribution. The NMCP is conducting drug resistance testing and the Malaria Match Box in order to incorporate key community, rights and gender issues into routing malaria programming and is planning for the development of the new MSP
Policy	Sign, ratify and deposit the AMA instrument at the AUC	Q1 2023		Deliverable not yet due

Central African Republic has responded positively to the recommended action on development and implementation of a national insecticide resistance monitoring and management plan and reporting on the status of insecticide resistance monitoring to WHO.

## **RMNCAH and NTDs**

Progress in addressing Neglected Tropical Diseases (NTDs) in Central African Republic is measured using a composite index calculated from preventive chemotherapy coverage achieved for lymphatic filariasis, onchocerciasis, schistosomiasis, soil transmitted helminths and trachoma. Preventive chemotherapy coverage in Central African Republic is very low for schistosomiasis (16%), low for soil transmitted helminths (43%), onchocerciasis (61%) and for trachoma (47%). It is good for lymphatic filariasis (77%). Overall, the NTD preventive chemotherapy coverage index for Central African Republic in 2021 is 43 and this represents a very substantial increase compared with the 2020 index value (0).

**Previous Key Recommended Actions** 

Objective	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
RMNCAH <sup>1</sup> : Impact	Ensure that essential RMNCAH services are sustained and implemented whilst using Covid-19 sensitive guidelines during the pandemic. Address any stock-outs of essential RMNCAH commodities	Q4 2022		The country reports no major disruptions in health services during the COVID-19 pandemic. An evaluation was carried out which demonstrated the continuity of sexual and reproductive health services
NTDs	Recognising the negative impact of COVID-19 on the 2020 MDA coverage, ensure that NTD interventions including MDAs, vector control and Morbidity Management and Disability Prevention are sustained and implemented whilst using Covid-19 sensitive guidelines during the pandemic. This includes conducting stock reconciliation following a national and subnational physical inventory count tracking of leftover stocks at district level and retrieving all expired drugs after MDA for incineration and accountability	Q4 2022		By respecting COVID-19 preventive measures, the country is conducting key NTD interventions. In 2022, the country conducted trachoma MDA and has been working to mobilize funds to increase the coverage of NTD prevention and control interventions. NTD routine activities have been conducted as planned despite security issues

The country has responded to the RMNCAH recommended actions addressing the lack of data for vitamin A and continues to track progress as this action is implemented.

**New Key Recommended Action** 

Objective	Action Item	Suggested completion timeframe
NTDs	Work to increase the preventive chemotherapy coverage for schistosomiasis, soil transmitted helminthiasis, Onchocerciasis and for trachoma and reach WHO targets. Ensure that NTD interventions including Mass Drug Administration, vector control and Morbidity Management and Disability Prevention are sustained and implemented. This includes prioritising key necessary catch-up activities as well as conducting stock reconciliation following a national and subnational physical inventory count tracking of leftover stocks at district level and retrieving all expired drugs after MDA for incineration and accountability	Q4 2023



<sup>&</sup>lt;sup>1</sup> RMNCAH metrics, recommended actions and response tracked through WHO